6.855  -0.665 (-8.84%)		12-15 15:59
Open: 7.627 High: 7.7 Volume: 155,510		Pre. Close: 7.52 Low: 6.68 Market Cap: 159(M)

Short term
Mid term
Targets	6-month :	9.22	1-year :	10.77
Resists	First :	7.9	Second :	9.22
Pivot price	7.2
Supports	First :	6.48	Second :	5.61
MAs	MA(5) :	7.37	MA(20) :	6.91
	MA(100) :	7.24	MA(250) :	0
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	70.9	D(3) :	79.1
RSI	RSI(14): 47.4
52-week	High :	11.98	Low :	5.46

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACTU ] has closed above bottom band by 29.8%. Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.72 - 7.76	7.76 - 7.79
Low:	6.59 - 6.63	6.63 - 6.67
Close:	6.79 - 6.86	6.86 - 6.92

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Mon, 15 Dec 2025
Actuate Therapeutics Announces Promising Phase II Study Results for Elraglusib in Advanced Salivary Gland Cancer - Quiver Quantitative

Mon, 08 Dec 2025
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU - MarketBeat

Sun, 07 Dec 2025
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - MSN

Fri, 28 Nov 2025
Actuate Therapeutics Signs $100M Sales Agreement - TipRanks

Fri, 28 Nov 2025
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Nasdaq

Thu, 27 Nov 2025
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	10 (M)
Held by Insiders	15.9 (%)
Held by Institutions	51.7 (%)
Shares Short	484 (K)
Shares Short P.Month	491 (K)

EPS	0.34
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.46
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-95.3 %
Return on Equity (ttm)	-296.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	20.16
PEG Ratio	0
Price to Book value	14.58
Price to Sales	0
Price to Cash Flow	-7.88

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.